Gilead seeks FDA OK for new 'TAF' combo drug
This article was originally published in Scrip
Executive Summary
Gilead Sciences is seeking the FDA's blessing to market a new fixed-dose combination (FDC) drug the firm is touting as a potential "backbone" for future HIV therapy regimens.